Here’s a structured comparison between Healed Gene’s IVD Test and Pharmacogenomic (PGx) Testing in the context of depression diagnosis and treatment, based on available research and the functionalities described:
1. Purpose and Scope
Healed Gene’s IVD Test:
Diagnostic: Detects the presence of depression (binary yes/no) and classifies severity (mild, moderate, severe) .
Treatment Prediction: Predicts efficacy for specific interventions (SSRIs/SNRIs, rTMS, ketamine, ECT), potentially guiding modality selection beyond pharmacotherapy.
PGx Testing:
Pharmacological Optimization: Focuses on gene-drug interactions to guide antidepressant selection and dosing, but does not diagnose depression or assess severity .
Limited to Medications: Primarily addresses metabolic pathways and adverse reaction risks .
2. Target Population
Healed Gene: Likely broader (all depression patients), especially for initial diagnosis and treatment selection.
PGx Testing: Best suited for treatment-resistant depression or patients with adverse drug reactions, as endorsed by psychiatric guidelines .
English 
